Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 02 2020
Historique:
received: 19 12 2018
revised: 28 05 2019
accepted: 30 10 2019
pubmed: 7 11 2019
medline: 18 8 2020
entrez: 7 11 2019
Statut: ppublish

Résumé

Acquired resistance to HER2-targeted therapies occurs frequently in HER2

Identifiants

pubmed: 31690671
pii: 0008-5472.CAN-18-3985
doi: 10.1158/0008-5472.CAN-18-3985
pmc: PMC7002225
mid: NIHMS1541926
doi:

Substances chimiques

ATP5F1B protein, human 0
Enzyme Inhibitors 0
Oligomycins 0
oligomycin A 05HQS4AI99
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
Mitochondrial Proton-Translocating ATPases EC 3.6.3.-
Trastuzumab P188ANX8CK

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

524-535

Subventions

Organisme : NCI NIH HHS
ID : R21 CA187862
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIA NIH HHS
ID : F32 AG052995
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA216101
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014195
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
PLoS Biol. 2018 Aug 6;16(8):e2006134
pubmed: 30080846
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Genet. 2014 Apr;46(4):364-70
pubmed: 24584072
Cancer Cell. 2004 Apr;5(4):317-28
pubmed: 15093539
Cancer Cell. 2014 Mar 17;25(3):282-303
pubmed: 24651011
Cell Cycle. 2008 Apr 15;7(8):1054-66
pubmed: 18414044
BMC Cancer. 2014 Jul 15;14:515
pubmed: 25026897
Toxicol In Vitro. 2007 Aug;21(5):902-11
pubmed: 17346924
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):1-6
pubmed: 28065746
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Cancer Res. 2011 Mar 1;71(5):1871-82
pubmed: 21324925
Cancer Cell. 2015 Oct 12;28(4):472-485
pubmed: 26461093
Br J Cancer. 2006 Jan 30;94(2):259-67
pubmed: 16404427
Nature. 2014 Oct 30;514(7524):628-32
pubmed: 25119024
Clin Cancer Res. 2015 Mar 15;21(6):1360-72
pubmed: 25547679
Cancer Res. 2001 Jun 15;61(12):4892-900
pubmed: 11406568
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Cancer Cell. 2013 Jun 10;23(6):811-25
pubmed: 23764003
Aging (Albany NY). 2016 Aug;8(8):1593-607
pubmed: 27344270
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
J Clin Oncol. 2014 Nov 20;32(33):3744-52
pubmed: 25332249
Cancer Res. 2000 Jul 1;60(13):3384-8
pubmed: 10910043
Cancer Res. 2001 Jun 15;61(12):4744-9
pubmed: 11406546
Cancer Cell. 2009 May 5;15(5):429-40
pubmed: 19411071
Nature. 2017 Nov 9;551(7679):247-250
pubmed: 29088702
Clin Cancer Res. 2018 Mar 1;24(5):1216-1226
pubmed: 29180608
J Clin Oncol. 2002 Feb 1;20(3):719-26
pubmed: 11821453
Cancer Cell. 2002 Aug;2(2):127-37
pubmed: 12204533
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Med. 2011 Apr;17(4):461-9
pubmed: 21399647
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Mol Cell. 2007 Oct 12;28(1):15-27
pubmed: 17936701
Biochim Biophys Acta. 2011 Jun;1807(6):543-51
pubmed: 21035425
Cell Stem Cell. 2017 Feb 2;20(2):233-246.e7
pubmed: 27989769
PLoS One. 2012;7(5):e37699
pubmed: 22629444
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Cancer Cell. 2004 Aug;6(2):117-27
pubmed: 15324695
Clin Med Insights Oncol. 2016 Mar 28;10(Suppl 1):21-30
pubmed: 27042153
J Natl Cancer Inst. 2015 May 19;107(8):null
pubmed: 25991002
Oncotarget. 2016 Jun 28;7(26):39931-39944
pubmed: 27224921
Biochim Biophys Acta. 2014 Dec;1846(2):353-65
pubmed: 25065528
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
Cancer Res. 2011 Jul 1;71(13):4585-97
pubmed: 21498634

Auteurs

Molly Gale (M)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Yao Li (Y)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Jian Cao (J)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

Zongzhi Z Liu (ZZ)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Marissa A Holmbeck (MA)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Meiling Zhang (M)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Sabine M Lang (SM)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Lizhen Wu (L)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Mariana Do Carmo (M)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Swati Gupta (S)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Keisuke Aoshima (K)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Laboratory of Comparative Pathology, Department of Clinical Veterinary Sciences, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.

Michael P DiGiovanna (MP)

Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.

David F Stern (DF)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

David L Rimm (DL)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

Gerald S Shadel (GS)

Salk Institute for Biological Studies, La Jolla, California.

Xiang Chen (X)

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China. qin.yan@yale.edu chenxiangck@126.com.
Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, Hunan, China.

Qin Yan (Q)

Department of Pathology, Yale School of Medicine, New Haven, Connecticut. qin.yan@yale.edu chenxiangck@126.com.
Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Yale Stem Cell Center, Yale School of Medicine, New Haven, Connecticut.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH